|Articles|December 1, 2009
- BioPharm International-12-01-2009
- Volume 22
- Issue 12
BioPharm International, December 2009 (PDF)
QbD in Practice–Part 2: The Regulatory Filing
Advertisement
Articles in this issue
almost 16 years ago
CDMOs Benefit from the Growing Biologics Marketalmost 16 years ago
Disposables in Rapid Response Manufacturing: The Next Stepsalmost 16 years ago
Quality by Design for Biotechnology Products—Part 2almost 16 years ago
Licensing of Expression Systemsalmost 16 years ago
The Promise and Perils of Vaccinesalmost 16 years ago
Speeding Up Slowlyalmost 16 years ago
Freeze-Thaw Performance and Robustness Assessment of Celsius FFT 6Lalmost 16 years ago
Faking ItNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
2
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
3
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
4
Selecting the Right Drug Delivery Formulations to Enhance Patient-Centric Care
5
